Vimarsana
Biggest News Aggregation in the World

Page 37 - Scientific Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scientific Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scientific Program Today - Breaking & Trending Today

10th UCG Edition on Diabetes and Endocrinology Conference - Vimarsana News

10th UCG Edition on Diabetes and Endocrinology Conference

KUAF 91.3 Public Radio serving parts of Arkansas, Oklahoma and Missouri with local, national & international news, music and entertainment.

Source: kuaf.com
Mount Sinai Alzheimer's Researcher Wins Rainwater Prize for Outstanding Innovation in Neurodegenerative Research - Vimarsana News

Mount Sinai Alzheimer's Researcher Wins Rainwater Prize for Outstanding Innovation in Neurodegenerative Research

The Rainwater Charitable Foundation has named Alison M. Goate, DPhil, the Jean C. and James W. Crystal Professor and Chair of Genetics and Genomic

Rainwater charitable foundation announces third-annual Rainwater Prize Winners - Vimarsana News

Rainwater charitable foundation announces third-annual Rainwater Prize Winners

Honorees are recognized for their innovative scientific discoveries for neurodegenerative diseases

Source: tass.com
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i - Vimarsana News

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

/PRNewswire/ -- Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in...